Table 1.
List of Small Molecule Kinase Inhibitors in Ongoing Pancreatic Cancer Clinical Trials
| Targets | Inhibitors | Drugs Combined in Trials | References |
|---|---|---|---|
| EGFR, ErbB2 | Lapatinib (GW572016) | Gemcitabine | * |
| Gemcitabine/oxaliplatin | [96] | ||
| Oxaliplatin/folinic acid/5-fluorouracil | [97] | ||
| Oxaliplatin, cetuximab | * | ||
| Erlotinib | Capecitabine | * | |
| MK-0646 (IGF-1R antibody), gemcitabine | [68] | ||
| Isoflavones, gemcitabine | [98] | ||
| Gemcitabine, IMC-A12 | [21] | ||
| Apricoxib, gemcitabine | [99] | ||
| Gemcitabine, capecitabine | [100] | ||
| Bevacizumab | [101] | ||
| Bevacizumab, gemcitabine, capecitabine | [102] | ||
| Gemcitabine | [103–105] | ||
| Gemcitabine vs. gemcitabine/docetaxel | [106] | ||
| Capecitabine, radiation | [107] | ||
| Rapamycin | [108] | ||
| Oxaliplatin | * | ||
| GDC-0449±gemcitabine | * | ||
| Gemcitabine, cisplatin | * | ||
| Pertuzumab | * | ||
| Gemcitabine+trastuzumab | * | ||
| ASD6244 (selumetinib) | * | ||
| Capecitabine, bevacizumab | * | ||
| Gemcitabine, nab-paclitaxel | * | ||
| VEGFR | Pazopanib | [109] | |
| Paclitaxel | [110] | ||
| Axitinib (AG013736) | Gemcitabine | [111] | |
| PDGFR | Imatinib (glivec) | Gemcitabine, oxaliplatin | [112] |
| IGF-1R | BMS-754807 | [69] | |
| mTOR | Temsirolimus (CCI-779) | [108, 113, 114] | |
| Everolimus (RAD001) | Gemcitabine | * | |
| Irinotecan, cetuximab | * | ||
| Cetuximab, capecitabine | * | ||
| MEK 1/2 | AS70326 (MSC1936369B) | * | |
| Multiple kinases | Sorafenib (Bay43-9006) | Tipifarnib | [115] |
| Gemcitabine | * | ||
| Gemcitabine, radiation | * | ||
| Everolimus | * | ||
| Erlotinib | * | ||
| GSK 1363089 (foretinib) | Gemcitabine | [116] | |
| Sunitinib | * | ||
| Src family | Saracatinib (AZD 0530) | [117] | |
| Dasatinib | * |